key: cord-0984384-4bzw6h37
authors: Ghosh, Ritwik; Biswas, Uttam; Roy, Dipayan; Pandit, Alak; Lahiri, Durjoy; Ray, Biman Kanti; Benito‐León, Julián
title: De Novo Movement Disorders and COVID‐19: Exploring the Interface
date: 2021-04-28
journal: Mov Disord Clin Pract
DOI: 10.1002/mdc3.13224
sha: 515426e2f65e897150eb742ccaded7881f00f4f1
doc_id: 984384
cord_uid: 4bzw6h37

BACKGROUND: Neurological manifestations of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) are being widely documented. However, movement disorders in the setting of 2019 coronavirus infectious disease (COVID‐19) have been a strikingly less discussed topic. OBJECTIVES: To summarize available pieces of evidence documenting de novo movement disorders in COVID‐19. METHODS: We used the existing PRISMA consensus statement. Data were collected from PubMed, EMBASE, Web of Science, and Scopus databases up to the 29th January, 2021, using pre‐specified searching strategies. RESULTS: Twenty‐two articles were selected for the qualitative synthesis. Among these, a total of 52 patients with de novo movement disorders were reported. Most of these had myoclonus, ataxia, tremor or a combination of these, while three had parkinsonism and one a functional disorder. In general, they were managed successfully by intravenous immunoglobulin or steroids. Some cases, primarily with myoclonus, could be ascribed to medication exposures, metabolic disturbances or severe hypoxia, meanwhile others to a post‐or para‐infectious immune‐mediated mechanism. SARS‐CoV‐2 could also invade the central nervous system, through vascular or retrograde axonal pathways, and cause movement disorders by two primary mechanisms. Firstly, through the downregulation of angiotensin‐converting enzyme 2 receptors, resulting in the imbalance of dopamine and norepinephrine; and secondly, the virus could cause cellular vacuolation, demyelination and gliosis, leading to encephalitis and associated movement disorders. CONCLUSION: De novo movement disorders are scantly reported in COVID‐19. The links between SARS‐CoV‐2 and movement disorders are not yet established. However, we should closely monitor COVID‐19 survivors for the possibility of post‐COVID movement disorders.

molecular mimicry and host susceptibility. 6, 7 In some instances, this immunological mimicry may result in the development of targeted antibodies against cell surface dopaminergic receptors in the basal ganglia. 8, 9 Similarly, anti-neuronal antibodies directed against the cerebellar fastigial nucleus and omnipause neurons in the brainstem may give rise to an opsoclonus-myoclonus syndrome, as reported in several infectious diseases. 10, 11 Japanese encephalitis (JE) is one of the viral diseases with a major spectrum of movement disorders among its clinical manifestations. 12 In this infection, there is structural damage involving the thalamus, brainstem and basal ganglia, resulting in damage to the cortico-basal ganglia-thalamocortical loop with resultant movement disorders. 12 Norepinephrine and dopamine have important roles in movement disorders associated with JE. 13 Indeed, low levels of catecholamines in JE-associated movement disorders compared to Parkinson's disease and other extrapyramidal symptoms have been reported and may be due to severe structural damage to the thalamus, basal ganglia and brainstem. 13 Analogous pathophysiological mechanisms are believed to be a feature of other flavivirus infections. 14, 15 Similarly, anti-basal ganglia antibodies targeted against large striatal neurons have been reported in infantile bilateral striatal necrosis after recent respiratory tract infection with Streptococcus spp, manifesting as dystonic movements. 16 In a significant number of cases, common herpetic encephalitis and JE have produced anti-N-methyl-daspartate receptor antibodies, resulting in diffuse encephalopathies and movement disorders. 17, 18 Over the years, human immunodeficiency virus (HIV) infection has been associated with a multitude of movement disorders due to either direct or secondary damage to the basal ganglia or its connections (aberrant immunological response), or as a result of drug therapy. 19 Parkinsonism as a complication of viral infections is well documented and has been associated with influenza, JE, enterovirus, Epstein-Barr, western equine encephalitis, dengue, hepatitis E, measles, herpes simplex, HIV, coxsackie and many other viruses. 15, [20] [21] [22] [23] [24] [25] [26] [27] [28] Further, acute post-infectious anti-neuronal antibody-mediated cerebellar ataxia is seen in numerous cases following viral encephalitis in children. 29 The influenza pandemic of 1918 is famous for the postinfectious complication known as encephalitis lethargica, 30, 31 characterized by a myriad of abnormal movements, i.e., postencephalitic parkinsonism, tremor, dystonia, chorea, myoclonus, and oculo-masticatorymyorhythmias. 32 Encephalitis and encephalopathies in COVID-19 are being reported commonly, 1 but surprisingly, reports of movement disorders are scant. 33 During a time in which the medical literature is witnessing a deluge of COVID-19 related papers, those that report COVID-19 induced movement disorders are meager.

The purpose of this review was to summarize available pieces of evidence documenting de novo movement disorders in COVID-19 patients. Indeed, the movement disorders that have been reported in those patients who have suffered from COVID-19 rather than on the people already living with diagnosed or undiagnosed movement disorders. We also analyzed several putative pathological mechanisms of development of movement disorders in SARS-CoV-2 infection and finally, assessed why there is a scarcity of de novo movement disorders.

We searched through the PubMed, Embase, Web of Science, and Scopus databases with the following keywords (["Parkinsonism" OR "Ataxia" OR "myoclonus" OR "tremor" OR "dystonia" OR "chorea" OR "movement disorders"] AND ["SARS-CoV-2" OR "COVID-19"]), up to 29th January 2021. The articles were imported into the Rayyan QCRI software. 34 We also handsearched additional COVID-19 specific articles using the reference list of the selected studies and relevant journal websites from 2019 to the current date for literature inclusion. To decrease publication bias, we invigilated the references of all studies potentially missed in the electrical search. Content experts also searched the gray literature of any relevant articles.

All peer-reviewed studies, including cohort, case-control studies, and case reports, which met the pre-specified inclusion and exclusion criteria, were included in this study.

Our inclusion criteria were as follows: (1) studies reporting COVID-19 associated movement disorders; (2) studies reporting of management and outcome of the cases; and (3) studies approved by an Ethics Committee or Institutional Review Board, along with mandatory written informed consent before inclusion. Only studies that were published in English were considered. Accordingly, we excluded the studies with the following criteria: (1) prior history of movement disorder; (2) insufficient data and, subsequently, failure to contact the authors; (3) nonclinical research, animal studies and reviews; and (4) duplicate publications. The references of the original articles and reviews identified were manually searched further for any article that has been missed out.

We excluded studies if COVID-19 had not been confirmed and those written in languages other than English. We also excluded review papers, viewpoints, commentaries, and studies where information related to neurological manifestations or movement disorders was not reported.

The titles and abstracts were studied by two reviewers independently, and selected studies underwent full-text review. For the studies that were included for this review, the following information was extracted: demographics, disease semiology, time to diagnosis, clinical history, diagnostic methods employed, including neuroimaging, therapy, final outcome, cerebrospinal fluid (CSF) study, and autoimmune encephalitis panel. The extracted information was qualitatively synthesized. Because the number of studies and patients were limited, quantitative synthesis was not carried out.

Qualitative data were expressed in percentages. Unit discordance among the variables was resolved by converting the variables to a standard unit of measurement. A P value <0.05 was considered statistically significant, but it could not be calculated due to insufficient data. A meta-analysis was planned to analyze the association of the demographic findings, symptoms, biochemical and neuroimaging parameters and outcomes, but was later omitted due to lack of sufficient data.

This is a review of published literature on de novo movement disorders in COVID-19 and did not involve any human or animal subjects. Hence, approval from an Ethics Committee was not applicable.

The selection process carried out according to the Preferred Reporting for Systematic Review and Meta-Analysis (PRISMA) consensus statement is shown in Figure 1 . The published cases are summarized in Table 1 . Twenty-two articles were finally selected for the qualitative synthesis. Among these, a total of 52 patients with de novo movement disorders were reported. Most of these had myoclonus, ataxia, tremor or a combination of these, while three had parkinsonism and one a functional disorder. Cases of post-infectious generalized myoclonus were firstly reported by Khoo et al. 35 and R abano-Su arez et al. 44 Anand et al. 38 in their case series, from three different centers, reported eight cases of myoclonus associated with SARS-CoV-2 infection; the cases had variable backgrounds, comorbidities and outcomes. 38 Seven of these eight patients had significant metabolic disturbances, hypoxemia and medication exposure, which may have contributed to the development of myoclonus. 38 Seven cases of opsoclonus-myoclonus syndrome, presumably parainfectious, were described by Emamikhah et al., 56 who inferred that COVID-19 was probably the initial trigger infection. Six of these cases also had voice tremors. 56 Authors of all the four manuscripts concluded that myoclonus was probably secondary to immune-mediated brain injury. 35, 38, 44, 56 Diezma-Martín et al. 43 reported a case of tremor and ataxia in a 70-year-old man following COVID-19. A similar case of gait ataxia was described by Balestrino et al. 45 in an aged patient with multiple comorbidities. Chaumont et al. 47 reported four cases of severe COVID-19 in male patients aged 50-70 years after weaning of mechanical ventilation and extubation. Among a myriad of neurological manifestations, the patients had upper limb myoclonus, which persisted 3 weeks after discharge and an immunoglobulin regimen. 47 Méndez-Guerrero et al. 46 reported a case of opsoclonus-myoclonus complex in a 58-year-old man with an asymmetric hypokinetic-rigid syndrome, in whom there was asymmetrically decreased presynaptic dopamine uptake in the putamen on I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (I-FP-CIT) dopamine transporter single photon emission computed tomography (DAT-SPECT). Schellekens et al. 48 reported the case of a 48-year-old man with a history of asymptomatic HIV infection who had a partially reverted picture of myoclonus-ataxia in the setting of COVID-19. Paterson et al. 49 described a total of 43 COVID-19 patients with neurological manifestations, among which seven had post-COVID-19 ataxia. Intriguingly, lower limb tremors were observed in a SARS-CoV-2 infected woman, which could neither be traced to neurological impairment on examination nor an infectious or hormonal etiology on serum testing. The authors categorized it as a "functional movement disorder threatening existential continuum". 50 In general, the patients were managed successfully by intravenous immunoglobulin or steroids. In a few patients, a multimodal approach was employed. In the case of Cohen et al. 39 the symptoms persisted even after treatment with steroids, pramipexole, and biperidine. Clonazepam was used alone or in combination with other drugs in multiple patients where the condition improved. 35, 38, 43, 44, 52, 53, 55, 56 In four cases, the patients improved without any specific treatment. 42, 45, 46 The positive effect of immunotherapy in many of the patients points towards that the pathogenetic mechanisms for the development of some movement disorders, following SARS-CoV-2 infection, may be mediated by aberrant immune-mediated injury.

During this ongoing pandemic, a plethora of neurological manifestations in COVID-19 affecting both the central and the peripheral nervous systems are being reported. 1 However, surprisingly, data regarding movement disorders are scarce. Movement disorders in COVID-19 might be an under-recognized neurological complication. Thus, in the present review, we have only found 52 patients with de novo movement disorders.

Regarding the pathophysiology of movement disorders in COVID-19 as a whole, there are currently three possible explanations. Firstly, many cases, mainly those with myoclonus, could be ascribed to drugs, metabolic disturbances, or simply severe hypoxia. 44 Further, cases of autoimmune encephalitis with subacute cerebellar syndrome and myoclonus, triggered by SARS-CoV-2 infection, have just started to surface, 51 as are therapyrelated complications, such as opsoclonus-myoclonus in COVID-19 therapy-induced serotonin syndrome. 42 Secondly, a post-or para-infectious immune-mediated mechanism somehow related to the inflammatory phase of COVID-19. In this sense, there are many reports in the literature of myoclonus or parkinsonism presenting shortly after the onset of infection. 15, [20] [21] [22] [23] [24] [25] [26] [27] [28] 57 Finally, the neuroinvasive potential of SARS-CoV in humans is well known. 58, 59 Notably, SARS-CoV, 60 as well as the H1N1 influenza virus, 61 when they are inoculated intranasally, could spread through a transneuronal route to firstand second-order structures connected with the olfactory bulb. SARS-CoV-2 is present in some COVID-19 patients in their cerebrospinal fluid. 1 This agrees with previous studies that have found antibodies to coronaviruses in the cerebrospinal fluid of patients with Parkinson's disease, 62 suggesting the potential of SARS-CoV-2 for causing parkinsonism. Interestingly, striatal dopaminergic neurons, microglia, and astrocytes of basal ganglia bear angiotensin-converting enzyme 2 (ACE-2), the receptor for SARS-CoV-2, 63, 64 which would create a pathway for the entry of this virus, affecting these structures. 65 The fact that hyposmia is one of the most prevalent symptoms of COVID-19 66 and that the olfactory system is early affected in alpha-synucleinopathies might be an intriguing coincidence. 67 However, it is notable that recent studies indicate that α-synuclein may participate in the innate immune response to any viral infection. 68 Sadasivan et al. 69 demonstrated that multiple hits by H1N1 infection and exposure to environmental toxins simultaneously may damage the dopaminergic neurons in substantia nigra to a greater extent than a single hit by any single agent. This potentially keeps alive the threat of development of post-COVID-19 parkinsonism as a delayed and long-term debility as it was in the pandemic of 1918. [70] [71] [72] The basal ganglia is involved in cases of encephalitis following infection with respiratory pathogens. 73 Fishman et al. 74 demonstrated that the murine coronavirus has neurotropic potential and particular predilection towards the involvement of the basal ganglia, resulting in extra-and intra-cellular vacuolation, neuronal loss, chronic demyelination and gliosis. As suggested, 74 75 regarding a case of SARS-CoV-2 associated hemorrhagic encephalitis involving the basal ganglia bilaterally, further supports the affinity of coronaviruses by these structures. A cross-sectional, retrospective, observational study by Chougar et al. 76 revealed two distinct patterns of brain parenchymal involvement in SARS-CoV-2 infection, including white matter enhancing lesions and basal ganglia abnormalities. Similarly, SARS-CoV-2 infection has been associated with immunemediated acute hemorrhagic encephalopathy involving brainstem and thalami 77 as well as with vasculopathic or demyelinating processes involving bilateral putamina. 78 Recently, both ACE-2 and transmembrane serine protease 2 (TMPRSS2) have been found to be expressed in human corneal epithelium, suggesting that ocular surface cells could also be a potential viral entry point. 79 SARS-CoV-2 could invade the central nervous system, through vascular or retrograde axonal pathways, and infect the striatal neurons (Fig. 2) . 80 From here onwards, there might be two primary mechanisms through which the virus may cause movement disorders (Fig. 2) . Firstly, the downregulation of ACE-2 receptors could result in an imbalance of neurotransmitter levels, 81 primarily dopamine and norepinephrine (Fig. 2) , leading to dopamine deficiency. Secondly, the virus could cause cellular vacuolation, demyelination, and gliosis, leading to encephalitis and associated movement disorders (Fig. 2) .

Movement disorders are now sparse among COVID-19 patients (Fig. 3) . In most cases of neurological complications associated with SARS-CoV-2 infection, the neural substrates for movement disorders are spared; in fact, pure cortical, corticosubcortical interface and deep white matter involvement predominates, as evidenced by various imaging-based studies. 76, [82] [83] [84] [85] Furthermore, movement disorders following an infectiousautoimmune process typically develop after a period of weeks to months. Hence, there remains a possibility that expected parenchymal changes in the brain are just waiting to reach a threshold level to manifest as delayed movement disorders. 41 On the other hand, the differential distribution of ACE-2 receptors and its ancillary protein co-regulators among several brain cell types may be the cause of more strokes and fewer movement disorders. 86 Finally, human coronavirus can lie dormant in the leukocytes for a long period and may manifest as delayed or persistent central nervous system infection, later giving rise to movement disorders. 87 Indeed, immune dysregulation brought about by SARS-CoV-2 infection 88 may lead to neurodegeneration 89 and potentially neurodegenerative movement disorders might manifest later. Notwithstanding, movement disorders are being increasingly documented because of the higher reporting frequency of COVID-19 cases worldwide.

There are some limitations in the current review. Given the notable asymmetry between the total number of affected cases and reported cases of de novo movement disorders in COVID-19, it can be assumed that cases are currently under-reported. The current review is based on a small number of cases, even after an extensive search of available literature. Examination performed on in-hospital patients wearing masks, mostly by videoconferencing, may perhaps explain the limited description of these conditions. Also, several of the available reports do not describe the timeline of events in an organized manner, making interpretation difficult. Laboratory, electroencephalography and neuroimaging features have also not been mentioned in detail in a few of the cases. In addition, there is considerable heterogeneity in the available data that may be considered a hindrance in advanced analysis. Finally, we have not included non-English articles. Despite these shortcomings, the present organized review will act as a preliminary guide for clinicians while dealing with movement disorders that appear in the setting of COVID-19.

In closing, only a few case reports have been published describing mainly patients suffering from myoclonus, parkinsonism, tremor, and ataxia. Some cases, mainly those with myoclonus, could be ascribed to medication exposures, metabolic disturbances, or by severe hypoxia, and others, to a post-or para-infectious immune-mediated mechanism somehow related to the inflammatory phase of COVID-19. SARS-CoV-2 could also invade the central nervous system through vascular or retrograde axonal pathways and cause movement disorders. Finally, although SARS-CoV-2 may cause neurodegeneration, leading to movement disorders, this link is not yet established. However, we should closely monitor COVID-19 survivors for the possibility of post-COVID movement disorders. For now, we must patiently and vigilantly wait for time to unravel whether "post-COVID movement disorder" will be an additional entity to add to the spectrum of movement disorders. 

Ethical Compliance Statement: Informed patient consent was not necessary for this work. The authors confirm that the approval of an institutional review board was not required for this work. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.

Funding of Sources and Conflict of Interest: No specific funding was received for this work. The authors declare that there are no conflicts of interest relevant to this work.

Financial Disclosures for the Previous 12 Months: The authors declare that there are no additional disclosures to report. ■

Neurological and neuropsychiatric impacts of COVID-19 pandemic

COVID-19 presenting with thalamic hemorrhage unmasking moyamoya angiopathy

Hallucinatory palinopsia in COVID-19 induced posterior reversible encephalopathy syndrome

Autonomic dysfunction heralding acute motor axonal neuropathy in COVID-19

Miller fisher syndrome and polyneuritis cranialis in COVID-19

Infection-mediated autoimmune movement disorders

Streptococcal mimicry and antibody-mediated cell signaling in the pathogenesis of Sydenham's chorea

Dopamine-2 receptor extracellular Nterminus regulates receptor surface availability and is the target of human pathogenic antibodies from children with movement and psychiatric disorders

Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders

Update on opsoclonus-myoclonus syndrome in adults

Opsoclonus-myoclonus syndrome

Japanese encephalitis: a review of the Indian perspective

Cerebrospinal fluid catecholamine levels in Japanese encephalitis patients with movement disorders

Natural and nosocomial infection in a patient with West Nile encephalitis and extrapyramidal movement disorders

Post-dengue parkinsonism

Post-streptococcal autoimmune dystonia with isolated bilateral striatal necrosis

Anti-N-methyl-Daspartate receptor encephalitis after herpes simplex virus-associated encephalitis: An emerging disease with diagnosis and therapeutic challenges

Japanese encephalitis can trigger anti-N-methyl-D-aspartate receptor encephalitis

Movement disorders and AIDS: a review

Spectrum of movement disorders in encephalitis

Viral etiology for Parkinson's disease-a possible role of influenza A virus infection

Post encephalitic parkinsonism following dengue viral infection

Evidence for an enterovirus as the cause of encephalitis lethargica

Reversible parkinsonism due to involvement of substantia nigra in Epstein-Barr virus encephalitis

Hepatitis E virus-associated acute encephalitic parkinsonism

Parkinsonism caused by viral encephalitis affecting the bilateral substantia Nigra

Viral parkinsonism

Post-infectious acute cerebellar ataxia in children

Encephalitis lethargica: a dying fall

The centennial lesson of encephalitis lethargica

Movement disorders associated with encephalitis lethargica: a video compilation

Whither art thou? Tremor Other Hyperkinet Mov

Rayyan-a web and mobile app for systematic reviews

Postinfectious brainstem encephalitis associated with SARS-CoV-2

Post-COVID-19 paradoxical vocal fold movement disorder

Myoclonus and cerebellar ataxia following coronavirus disease 2019 (COVID-19)

Myoclonus in patients with coronavirus disease 2019: a multicenter case series

A case of probable Parkinson's disease after SARS-CoV-2 infection

Coronavirus disease 2019 and parkinsonism: a non-postencephalitic case

Movement disorders as a new neurological clinical picture in severe SARS-CoV-2 infection

Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir

Tremor and ataxia in COVID-19

Generalized myoclonus in COVID-19

Onset of Covid-19 with impaired consciousness and ataxia: a case report

Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection

Mixed central and peripheral nervous system disorders in severe SARS-CoV-2 infection

Reversible myoclonus-ataxia as a postinfectious manifestation of COVID-19

The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings

Functional movement disorders in a patient with COVID-19

Autoimmune encephalitis concomitant with SARS-CoV-2 infection: insight from (18) F-FDG PET imaging and neuronal autoantibodies

Diaphragmatic myoclonus due to SARS-CoV-2 infection

Opsoclonus myoclonus ataxia syndrome in the setting of COVID-19 infection

Subcortical myoclonus in COVID-19: comprehensive evaluation of a patient

Post-hypoxic myoclonus after COVID-19 infection recovery

Opsoclonus-myoclonus syndrome, a post-infectious neurologic complication of COVID-19: case series and review of literature

Isolated" postinfectious myoclonus

Multiple organ infection and the pathogenesis of SARS

Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis

Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2

H1N1 influenza virus replicates and induces proinflammatory cytokine responses in extrarespiratory tissues of ferrets

Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson's disease

The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease

Angiotensin type 2 receptors: role in aging and neuroinflammation in the substantia nigra

Structure of the SARS-CoV-2 spike receptorbinding domain bound to the ACE2 receptor

Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): A multicenter European study

The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases

Can infections trigger alpha-synucleinopathies?

Synergistic effects of influenza and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) can be eliminated by the use of influenza therapeutics: Experimental evidence for the multi-hit hypothesis

A post-COVID-19 parkinsonism in the future?

The impact of the COVID-19 pandemic on Parkinson's disease: hidden sorrows and emerging opportunities

COVID-19 and Parkinson's disease: are we dealing with short-term impacts or something worse?

Encephalitis with thalamic and basal ganglia abnormalities: etiologies, neuroimaging, and potential role of respiratory viruses

Infection of the basal ganglia by a murine coronavirus

Basal ganglia involvement and altered mental status: a unique neurological manifestation of coronavirus disease 2019

Retrospective observational study of brain magnetic resonance imaging findings in patients with acute SARS-CoV-2 infection and neurological manifestations

COVID-19-related acute necrotizing encephalopathy with brain stem involvement in a patient with aplastic anemia

COVID-19-white matter and globus pallidum lesions: demyelination or small-vessel vasculitis?

ACE2 and TMPRSS2 are expressed on the human ocular surface, suggesting susceptibility to SARS-CoV-2 infection

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated

An alteration of the dopamine synthetic pathway is possibly involved in the pathophysiology of COVID-19

Brain MRI findings in patients in the intensive care unit with COVID-19 infection

Nervous system involvement in COVID-19: results from a retrospective consecutive neuroimaging cohort

Brain MRI findings in severe COVID-19: a retrospective observational study

Early postmortem brain MRI findings in COVID-19 non-survivors

Altered COVID-19 receptor ACE2 expression in a higher risk group for cerebrovascular disease and ischemic stroke

Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system?

Immune pathogenesis of COVID-19 intoxication: storm or silence?

SARS-CoV-2: at the crossroad between aging and neurodegeneration